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❚ Evidence summary
Oral agents are commonly prescribed for
patients with diabetes mellitus type 2
when diet and exercise fail. Options for
initiating therapy include sulfonylureas,
metformin (Glucophage), α-glucosidase
inhibitors, thiazolidinediones, and non-
sulfonylurea secretagogues (repaglinide
[Prandin] and nateglinide [Starlix]). 
A systematic review with 31 placebo-
controlled randomized trials (total
n=12,185 patients) evaluated changes in
HbA1c with monotherapy using 5 differ-
ent classes of oral agents (TABLE).1 Except
for the α-glucosidase inhibitor acarbose
(Precose), which was less effective, all
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What is the best medical therapy 
for new-onset type 2 diabetes?
Sulfonylureas, metformin, thiazolidinediones,
and non-sulfonylurea secretagogues differ
little in their ability to decrease glycosylated
hemoglobin (HbA1c) levels when used as ini-
tial monotherapy for diabetes mellitus type 2
(strength of recommendation [SOR]: A,
based on systematic reviews); α-gluco-
sidase inhibitors may also be as effective
(SOR: B, based on systematic reviews with
inconsistent results). Metformin is generally
indicated in obese patients because it
improves all-cause mortality and diabetes
related outcomes (SOR: B, based on a sin-
gle high-quality randomized controlled trial
[RCT]). Insulin is generally not recommended
as an initial agent (SOR: C, expert opinion).
E V I D E N C E - B A S E D A N SW E R
Consider the advantages of each class
to best meet your patient’s goals
Lifestyle modification is the cornerstone of
initial treatment of type 2 diabetes. However,
in clinical practice, medications (monothera-
py or combination therapy) are often started
along with diet and exercise recommenda-
tions. Physicians and patients should clearly
understand the treatment goals before initi-
ating therapy. Multiple factors often influ-
ence treatment goals, such as presence or
absence of symptoms, age-related risks
from potential hypoglycemia, degree of
hyperglycemia, presence of morbidities
(renal insufficiency, heart failure, obesity),
cost of the medication, as well as patient or
physician preferences. Despite their com-
parable efficacy in the reduction of HbA1c
level, each class of oral hypoglycemic med-
ication has a different mechanism of action
and adverse side-effect profile. Therefore,
physicians must consider the advantages
and disadvantages of each class to choose
a medication regimen that best meets their
patient’s individual treatment goals.
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agents typically reduced HbA1c by 1% to
2%. However, in an additional 19 out of
23 randomized head-to-head studies
(total n=5396) included in the same sys-
tematic review, all classes showed equal
efficacy.
Head-to-head studies are difficult to
compare since hypoglycemic medications
may reach peak effects at different times.
An RCT compared glimepiride (Amaryl),
pioglitazone (Actos), and metformin over
12 months of use by 114 patients with
diabetes.3 There was no difference among
the groups in overall HbA1c reduction.
However, glimepiride decreased HbA1c
rapidly over 1 month and reached a nadir
at 4 months. Pioglitazone did not reduce
HbA1c until 6 months and reached its
nadir at 7 to 9 months. Metformin pro-
duced an intermediate response. 
A meta-analysis of head to head stud-
ies involving α-glucosidase inhibitors
included 8 trials comparing acarbose with
sulfonylureas. In pooled results, sulfony-
lureas trended towards greater HbA1c
reduction but did not reach significance
(additional HbA1c decrease 0.4%; 95%
confidence interval [CI], 0%–0.8%).4
A meta-analysis of head-to-head
studies involving metformin showed
equal efficacy compared with injected
insulin (2 trials, 811 participants), α-glu-
cosidase inhibitors (2 trials, 223 partici-
pants), and non-sulfonylurea secreta-
gogues (2 trials, 413 participants).5 In 12
trials with 2067 patients, metformin
decreased HbA1c more than sulfonylureas
did (standardized mean difference [SMD]
–0.14; 95% CI, –0.28 to –0.01). In 3 tri-
als with 246 patients, metformin also
produced greater HbA1c decreases than
thiazolidinediones (SMD –0.28; 95% CI,
–0.52 to –0.03). In the United Kingdom
Prospective Diabetes Study (UKPDS),
metformin improved diabetes-related out-
comes and all-cause mortality in obese
patients (relative risk of mortality=0.73;
95% CI, 0.55–0.97; P=.03; number need-
ed to treat [NNT]=19).6
A systematic review with 22 RCTs
(total n=7370), ranging in length from 12
weeks to 3 years, compared 2 oral agents
with a single oral agent or placebo.1
Combinations of oral agents produced
statistically significant additional
improvement in HbA1c in 21 of 22 stud-
ies. The magnitude of this effect across
the studies was on the order of a 1%
Metformin
improved 
diabetes-related
outcomes and 
all-cause mortality 
in obese patients
FAST TRACK
TA B L E
CLASS DOSING TYPICAL HBA1C COST
INTERVAL REDUCTION* PER MONTH† CONTRAINDICATIONS/CAUTIONS
Sulfonylureas 1x daily 1.4%–1.8% $ DKA, caution in hepatic or renal disease
Metformin 1–2x daily 1.1%–2.0% $$ Congestive heart failure, acute or chronic metabolic   
acidosis,Cr ≥1.5 male, Cr ≥1.4 female, COPD, severe 
hepatic disease, alcoholism. Use caution in the elderly.
α-glucosidase 3x daily 0.6%–1.0% $$$ Cr ≥2.0, abnormal baseline liver function tests,
inhibitors inflammatory bowel disease
Thiazolidinediones 1–2x daily 1.5%–1.6% $$$–$$$$ Class III to IV heart failure, baseline ALT >2.5
Non-sulfonylurea 3x daily 1.8%–1.9% $$–$$$ Caution with liver disease
secretagogues
* The “typical” range excludes the studies with the highest and lowest measured effects.
† $ = $0 to $25; $$ = $25 to $60; $$$ = $60 to $120; $$$$ = $120 to $180.
DKA, diabetic ketoacidosis; Cr, chromium; COPD, chronic obstructive pulmonary disease; ALT, alanine transaminease.
Oral medications as monotherapy in type 2 diabetes mellitus1,2
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change in HbA1c, although the data were
not subject to a formal meta-analysis. 
Inhaled insulin may expand the list of
initial therapies for type 2 diabetes. A 12-
week manufacturer-sponsored RCT with
134 patients (mean HbA1c=9.5) com-
pared inhaled insulin with rosiglitazone
(Avandia).7 More patients using inhaled
insulin achieved an HbA1c <8.0 (82.7%
vs 58.2%; P=.0003); however, inhaled
insulin produced more adverse effects,
including cough and hypoglycemia. 
Recommendations from others
The International Diabetes Federation
(IDF) recommends metformin as the ini-
tial oral agent unless contraindicated.8 A
sulfonylurea is an acceptable alternative
in patients who are not overweight. The
IDF states that insulin should be added
when oral agents fail. 
The Institute for Clinical Systems
Improvement (ICSI) says that the “single
best choice drug for oral agent therapy
for type 2 diabetes has not been deter-
mined” and must be chosen in the context
of age, weight, and other comorbidities.9
The ICSI suggests metformin as an appro-
priate first agent for obese patients and
recommends sulfonylureas or metformin
as monotherapy for others because they
are both economical and well tolerated.
The American Diabetes Association does
not specifically recommend a best initial
agent or combination of agents for type 2
diabetes.10
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Patients on inhaled
insulin achieved
an HbA1c of less
than 8, but also
had more 
adverse effects
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